Related Experiment Videos
Protective properties of peptidoglycan associated protein of Shigella flexneri
Abstract:
Groups of CH3/Hej mice were immunized with peptidoglycan associated protein (PGP) from Shigella flexneri 3a administered in a single intraperitoneal injection (5 micrograms per mouse). After various periods post immunization the animals were challenged intraperitoneally with homologous bacteria. PGP proved to be strongly immunogenic. As early as one week after immunization all the animals survived challenge with 100 X LD100, and one third of the animals survived challenge with a dose of 500 X LD100. This high state of immunity maintained at almost unaltered intensity for 12 weeks after immunization (the end of the observations period).
Insights
Immunizing mice with Shigella flexneri 3a peptidoglycan associated protein (PGP) generated a robust immune response. Vaccinated mice demonstrated significant survival rates against lethal bacterial challenges for up to 12 weeks.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Shigella flexneri is a significant cause of bacterial dysentery.
- Developing effective vaccines against Shigella infections remains a public health priority.
Purpose of the Study:
- To evaluate the immunogenicity of peptidoglycan associated protein (PGP) from Shigella flexneri 3a.
- To assess the protective efficacy of PGP immunization in a mouse model.
Main Methods:
- CH3/Hej mice were immunized intraperitoneally with 5 micrograms of Shigella flexneri 3a PGP.
- Animals were subsequently challenged with homologous bacteria at varying doses (100X and 500X LD100).
- Immune response and survival rates were monitored over a 12-week period.
Main Results:
- Peptidoglycan associated protein (PGP) was found to be highly immunogenic.
- One week post-immunization, all mice survived a 100X LD100 challenge.
- One-third of the mice survived a 500X LD100 challenge.
- High immunity levels persisted for 12 weeks.
Conclusions:
- Shigella flexneri 3a PGP is a promising candidate for vaccine development.
- PGP immunization confers significant and long-lasting protection against homologous bacterial challenge.
- Further research into PGP-based vaccines for Shigella infections is warranted.